Royalty Pharma
RPRX
RPRX
278 hedge funds and large institutions have $10.5B invested in Royalty Pharma in 2022 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 129 increasing their positions, 59 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
0.01% less ownership
Funds ownership: 62.46% → 62.45% (-0.01%)
1% less capital invested
Capital invested by funds: $10.7B → $10.5B (-$150M)
18% less funds holding in top 10
Funds holding in top 10: 11 → 9 (-2)
Holders
278
Holding in Top 10
9
Calls
$39.2M
Puts
$3.92M
Top Buyers
| 1 | +$239M | |
| 2 | +$86.6M | |
| 3 | +$60.7M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$53.4M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$43.9M |
Top Sellers
| 1 | -$279M | |
| 2 | -$138M | |
| 3 | -$105M | |
| 4 |
VCG
Vantage Consulting Group
Virginia Beach,
Virginia
|
-$73M |
| 5 |
MSKCC
Memorial Sloan Kettering Cancer Center
New York
|
-$60.5M |